Stifel Expands Venture Banking Team to Accelerate Growth in Life Sciences and Healthcare Sectors

Rhea-AI Summary

Stifel Financial Corp. (NYSE: SF) has announced a significant expansion of its Venture Banking team with the addition of several senior bankers from Silicon Valley Bank, focusing on life sciences and healthcare sectors. The expansion is led by six Managing Directors - Jackie Spencer, Anthony Flores, Milo Bissin, Julie Ebert, Timothy Lew, and Sam Subilia - along with three Vice Presidents.

The move strengthens Stifel's Venture & Fund Banking division, which has already achieved notable growth with over 100 bankers, more than $10 billion in loan commitments, and doubled venture client deposits in the past year. The company has recently demonstrated its market strength by acting as joint bookrunner on 4 biopharma financings totaling $1.1 billion, including the first biopharma IPO in seven months.

This strategic expansion enhances Stifel's capabilities in supporting innovation-driven companies across biotech, diagnostics and tools, medical devices, and healthtech sectors.

News Market Reaction

-0.13%

1 alert

-0.13% News Effect

On the day this news was published, SF declined 0.13%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ST. LOUIS, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced a major expansion of its Venture Banking team, welcoming a new group of senior bankers, formerly from Silicon Valley Bank, who bring deep expertise across the life sciences and healthcare ecosystem. This strategic move reinforces Stifel’s commitment to supporting innovation-driven companies and investors in sectors such as biotech, diagnostics and tools, medical devices, and healthtech.

The new hires are led by Managing Directors Jackie Spencer, Anthony Flores, Milo Bissin, Julie Ebert, Timothy Lew, and Sam Subilia, all recognized for their success in venture banking, corporate finance, and strategic advisory. Collectively, they have advised and supported hundreds of early- and growth-stage companies, with backgrounds spanning commercial banking, venture debt, and investment banking at leading institutions. Vice Presidents Tessa Dibble, Lindsey Seidner, and Ariana DaCruz also join Stifel as part of the senior team.

This expansion builds on Stifel Bank’s recent momentum in Venture & Fund Banking, which has seen the team grow to over 100 bankers, more than $10 billion in loan commitments, and a more than doubling of venture client deposits in the past year.

“Stifel is proud to be a leading partner to the innovation ecosystem,” said Ronald J. Kruszewski, Chairman and CEO of Stifel. “Adding this talented team further strengthens our capabilities in healthcare and life sciences and expands the resources we provide to founders and investors.”

“The life sciences and healthcare sectors are at a critical inflection point, driven by the transformative potential of AI,” noted Jackie Spencer. “We are excited to bring our expertise to Stifel’s broader platform, which is uniquely positioned to provide founders and management teams with the resources and solutions to scale from inception to exit.”

Beyond venture banking, Stifel’s life sciences and healthcare focus spans equity research, capital raising, mergers and acquisitions, plus proprietary conferences and events. Since early September, Stifel has acted as joint bookrunner on 4 biopharma financings raising $1.1 billion, including the first biopharma IPO in seven months.

Stifel Company Information
Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; and Stifel Independent Advisors, LLC. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust, Members FDIC, offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A., Members FDIC, offer trust and related services. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit https://www.stifel.com/investor-relations/press-releases.

Media Contact
Neil Shapiro, +1 (212) 271-3447
shapiron@stifel.com

Investor Relations Contact
Joel Jeffrey, +1 (212) 271-3610
investorrelations@stifel.com

FAQ

What major expansion did Stifel (NYSE:SF) announce in September 2025?

Stifel announced the expansion of its Venture Banking team by hiring several senior bankers from Silicon Valley Bank, including six Managing Directors and three Vice Presidents, to strengthen its life sciences and healthcare sectors focus.

How large is Stifel's Venture & Fund Banking division as of 2025?

Stifel's Venture & Fund Banking division has grown to over 100 bankers with more than $10 billion in loan commitments, and has seen venture client deposits more than double in the past year.

Who are the key Managing Directors joining Stifel's Venture Banking team?

The new Managing Directors joining Stifel are Jackie Spencer, Anthony Flores, Milo Bissin, Julie Ebert, Timothy Lew, and Sam Subilia, all former Silicon Valley Bank executives.

What recent biopharma financing achievements has Stifel (SF) accomplished?

Stifel has acted as joint bookrunner on 4 biopharma financings raising $1.1 billion, including the first biopharma IPO in seven months.

How will this expansion affect Stifel's healthcare and life sciences capabilities?

The expansion strengthens Stifel's capabilities in supporting innovation-driven companies across biotech, diagnostics and tools, medical devices, and healthtech sectors, leveraging the new team's expertise in venture banking and corporate finance.